Biotech Values

[DewDiligence]

mcbio et al: I don’t take SCLN’s HCV program seriously. Here’s the relevant text from the PR you cited:

SCV-07 demonstrated activity in some treated patients in the higher dosage groups, and the decrease in viral load in these patients was accompanied by an increase in an immunological biomarker [which one?] which is usually correlated with response against HCV.

Too many waffle words here to infer much of anything. The description sounds like something PPHM might have written.